Opiant Pharmaceuticals, Inc. (OPNT): Price and Financial Metrics


Opiant Pharmaceuticals, Inc. (OPNT)

Today's Latest Price: $9.19 USD

0.05 (0.55%)

Updated Aug 7 4:00pm

Add OPNT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

OPNT Stock Summary

  • With a price/earnings ratio of 3.37, Opiant Pharmaceuticals Inc P/E ratio is greater than that of about merely 3.36% of stocks in our set with positive earnings.
  • For OPNT, its debt to operating expenses ratio is greater than that reported by just 6.53% of US equities we're observing.
  • Revenue growth over the past 12 months for Opiant Pharmaceuticals Inc comes in at 122.25%, a number that bests 95.16% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Opiant Pharmaceuticals Inc, a group of peers worth examining would be LTRX, PRGS, CGNX, TRIP, and SNCR.
  • Visit OPNT's SEC page to see the company's official filings. To visit the company's web site, go to www.opiant.com.
OPNT Daily Price Range
OPNT 52-Week Price Range

OPNT Stock Price Chart Technical Analysis Charts


OPNT Price/Volume Stats

Current price $9.19 52-week high $18.23
Prev. close $9.14 52-week low $8.05
Day low $8.97 Volume 51,100
Day high $9.40 Avg. volume 41,193
50-day MA $9.42 Dividend yield N/A
200-day MA $11.74 Market Cap 39.13M

Opiant Pharmaceuticals, Inc. (OPNT) Company Bio


Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is based in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.





OPNT Latest News Stream


Event/Time News Detail
Loading, please wait...

OPNT Latest Social Stream


Loading social stream, please wait...

View Full OPNT Social Stream

Latest OPNT News From Around the Web

Below are the latest news stories about Opiant Pharmaceuticals Inc that investors may wish to consider to help them evaluate OPNT as an investment opportunity.

Opiant Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

SANTA MONICA, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its second quarter 2020 financial results after the financial markets close on Thursday August 6, 2020.   The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday August 6, 2020. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13706176. To access the live webcast, please go to the investors section of Opiant’s website at http://ir.opiant.com/. Following the live webcast, an archived version of the call will be available on the ...

Yahoo | July 23, 2020

Edited Transcript of OPNT earnings conference call or presentation 12-May-20 8:30pm GMT

Q1 2020 Opiant Pharmaceuticals Inc Earnings Call

Yahoo | June 30, 2020

Teva prevails in Narcan patent dispute with Opiant

Opiant Pharmaceuticals (OPNT) reports that a New Jersey district court has ruled in favor of Teva Pharmaceutical Industries (TEVA) in a patent infringement lawsuit brought by Opiant in response to Teva's U.S. application seeking approval to market a generic version of opioid overdose med Narcan (naloxone HCl) Nasal Spray.The company...

Seeking Alpha | June 6, 2020

Opiant Pharmaceuticals Statement on U.S. District Court Decision

SANTA MONICA, Calif., June 05, 2020 -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone.

Yahoo | June 6, 2020

Opiant Pharmaceuticals to Present at the 2020 Jefferies Virtual Healthcare Conference

SANTA MONICA, Calif., May 26, 2020 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.

Yahoo | May 26, 2020

Read More 'OPNT' Stories Here

OPNT Price Returns

1-mo -1.18%
3-mo -22.03%
6-mo -25.16%
1-year -34.31%
3-year -61.01%
5-year 25.89%
YTD -36.18%
2019 -0.35%
2018 -37.09%
2017 309.45%
2016 -43.05%
2015 N/A

Continue Researching OPNT

Here are a few links from around the web to help you further your research on Opiant Pharmaceuticals Inc's stock as an investment opportunity:

Opiant Pharmaceuticals Inc (OPNT) Stock Price | Nasdaq
Opiant Pharmaceuticals Inc (OPNT) Stock Quote, History and News - Yahoo Finance
Opiant Pharmaceuticals Inc (OPNT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0246 seconds.